| TSBP1-AS1 |
|
TSBP1 and BTNL2 antisense RNA 1
|
|
|
0.638 |
0.692 |
39
|
318 |
| ABO |
P16442
|
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
|
Enzyme
|
|
0.427 |
0.885 |
26
|
135 |
| HLA-DRB9 |
|
major histocompatibility complex, class II, DR beta 9 (pseudogene)
|
|
|
0.682 |
0.654 |
21
|
47 |
| CDKN2B-AS1 |
|
CDKN2B antisense RNA 1
|
|
|
0.491 |
0.769 |
21
|
151 |
| LINC02571 |
|
long intergenic non-protein coding RNA 2571
|
|
|
0.743 |
0.500 |
18
|
42 |
| LINC00243 |
|
long intergenic non-protein coding RNA 243
|
|
|
0.729 |
0.423 |
15
|
27 |
| HCP5 |
Q6MZN7
|
HLA complex P5
|
|
|
0.595 |
0.808 |
14
|
16 |
| HNF1A-AS1 |
|
HNF1A antisense RNA 1
|
|
|
0.621 |
0.538 |
13
|
10 |
| ZNRD1ASP |
|
zinc ribbon domain containing 1 antisense, pseudogene
|
|
|
0.691 |
0.538 |
12
|
12 |
| HCG18 |
|
HLA complex group 18
|
|
|
0.722 |
0.538 |
12
|
7 |
| HCG17 |
|
HLA complex group 17
|
|
|
0.769 |
0.346 |
12
|
12 |
| ATP6V1G2-DDX39B |
|
ATP6V1G2-DDX39B readthrough (NMD candidate)
|
|
|
0.769 |
0.423 |
12
|
20 |
| IL12A-AS1 |
|
IL12A antisense RNA 1
|
|
|
0.633 |
0.654 |
12
|
32 |
| HCG9 |
|
HLA complex group 9
|
|
|
0.700 |
0.500 |
9
|
5 |
| HCG22 |
E2RYF7
|
HLA complex group 22 (gene/pseudogene)
|
|
|
0.736 |
0.423 |
9
|
11 |
| PPT2-EGFL8 |
|
PPT2-EGFL8 readthrough (NMD candidate)
|
|
|
0.792 |
0.462 |
9
|
10 |
| TH2LCRR |
|
T helper type 2 locus control region associated RNA
|
|
|
0.751 |
0.385 |
9
|
8 |
| MIR4435-2HG |
|
MIR4435-2 host gene
|
|
|
0.604 |
0.692 |
8
|
13 |
| MIR3936HG |
|
MIR3936 host gene
|
|
|
0.861 |
0.269 |
8
|
8 |
| MSH5-SAPCD1 |
|
MSH5-SAPCD1 readthrough (NMD candidate)
|
|
|
0.760 |
0.423 |
8
|
10 |
| LINC02210-CRHR1 |
P34998
|
LINC02210-CRHR1 readthrough
|
|
|
0.570 |
0.692 |
8
|
204 |
| MAPT-AS1 |
|
MAPT antisense RNA 1
|
|
|
0.711 |
0.269 |
7
|
114 |
| USP8P1 |
|
USP8 pseudogene 1
|
|
|
0.805 |
0.269 |
7
|
7 |
| APOC4-APOC2 |
|
APOC4-APOC2 readthrough (NMD candidate)
|
|
|
0.821 |
0.308 |
7
|
5 |